Navigating the Evolving FDA & EMA Guidance to Accelerate Approval of MDMA, Psilocybin & DMT-Derived Therapies
Time: 3:30 pm
day: Day Two PM
Details:
- Reviewing the latest regulatory research in the psychedelic field
- Tackling the unique regulatory hurdles of MDMA vs psilocybin vs DMT
- Regulatory considerations for psychedelic trials, phase 1-3
